Anavex Life Sciences Corp (AVXL)

[McMagyar]

respnse to cory de shortliar of a Fool of You 4 Me:
So you found someone named Dr. Hendrix to say Placebo Effect renders results meaningless? That is an outrageous LIE! The Placebo Effect for Alzheimer's Patients is rendered NON-EXISTANT after 12 Weeks or LESS! To have an EFFECT ..ANY EFFECT after 8 Months is PK-Action-AKA -Curative! I understand a lot of people SHORT STOCKS and MAKE MONEY when they go down..but WHY DO PEOPLE HAVE TO LIE and OBFUSCATE GREAT NEWS and HOPE in order to make a dollar. It is sick.
Placebo Effect for AD is documented that at 12 Weeks almost ALL Placebo Control Patients not ONLY do NOT show Placebo Effect, which at 5Weeks may have been eual to or as stong as Aricept-still very weak- but thier ADCS-ADL numbers revert all the way back to Patient Group that received ZERO Pills. Dr. Hendrix has ZERO credibility, as does this author, who has previously written a hit piece regarding Anavex. Cory has written other postive articles about Alzheimers Drugs and the Market Opportunity that they present..Hmm..here is what Cory said when he was pumping up Biogen after a Phase 1b study!

http://seekingalpha.com/.../2731695-what-biogen-idecs...

They couldn't play the Piano yet or paint ..but Cory was PAINTING QUITE the picture for Biogen! biogen went up $29 BILLION in Market Cap..only to lose it.
Maybe Cory is still paying off that debt by Trashing the renewed Artistry of Cured Alzheimers Paitents with Anavex!
Cory might be slowing down the process of sick people getting mediicine ..the real question is ..Why?,
Here is a 24 wwek study showing at 6 weeks Placebo-Effect and Aricept have same effect but ever after the Placebo Group is GONE!

The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. The primary efficacy measures were the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of Change-Plus (CIBIC plus), with the Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale-Sum of the Boxes (CDR-SB), and patient rated Quality of Life (QoL) used as secondary measures. Cognitive function, as measured by the ADAS-cog, was significantly improved in the 5- and 10-mg/d donepezil groups as compared with the placebo group at weeks 12, 18, and 24. Clinician's global ratings on the CIBIC plus also improved in both the 5- and 10-mg/d donepezil groups relative to placebo. At the end of the 6-week placebo washout phase, ADAS-cog scores and CIBIC plus ratings were not significantly different for the three groups. Significant treatment benefits were also observed consistently in both the 5- and 10-mg/d groups on the MMSE and the CDR-SB, but there was no consistent effect on the patient-rated QoL. Cholinergic side effects (primarily diarrhea, nausea, and vomiting) were reported more often in the 10-mg/d group than either the 5-mg/d or placebo groups. Side effects were transient and generally mild in severity. These data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.

This is repeated Time after Time rendering Placebo Control Groups meaningless for succesful AD Treatments..You only need them if YOUR DRUG is BARELY WORKING!
Anavex is ROCKING OUT the Treatment! Playing the Piano, Painting are PLACEBO EFFECTS at 8 Months?
This is truly a SICK ARTICLE!